|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Systemic therapy for cervical carcinoma–current status显示文摘Two major treatment modalities in cervical cancer are radiation therapy(RT) and surgery. Chemotherapy continues to be the main form of systemic therapy adjunctive to definitive local therapies, and is used for palliation.Platinum-based regimens, administered concurrently with both definitive and postoperative RT, were demonstrated to provide significant survival benefits, whereas the beneficial effect of concurrent chemoradiotherapy in later-stage disease was smaller. The role of chemotherapy in addition to RT in IB1/IIA1 cervical cancer patients not undergoing surgery remains undefined. Likewise, the role of chemotherapy in combination with postoperative RT for patients with intermediate-risk factors for recurrence has not yet been verified. The recent standard for chemoradiotherapy is cisplatin alone administered weekly. Other cisplatin-based or non-cisplatin-based regimens have not been subjected to large clinical studies. The benefits of consolidation chemotherapy after chemoradiation for locally advanced cervical cancer are still undetermined. Neoadjuvant cisplatin-based chemotherapy followed by surgery has shown survival benefits, however its role in the era of chemoradiotherapy remains unclear. The combination of cisplatin and paclitaxel is considered a standard regimen in the palliative setting. There is no standard of care for second-line systemic therapy in advanced cervical cancer.Bevacizumab combined with palliative chemotherapy(cisplatin/paclitaxel or topotecan/paclitaxel) in the first-line treatment for recurrent/metastatic cervical cancer significantly improves overall survival when compared to chemotherapy alone. The role of immunotherapy in cervical cancer remains to be established. The optimal combined modality treatment including systemic therapy for cervical tumors of non-squamous histology remains a matter of debate. Ongoing accumulation of data on genomic and proteomic characteristics provides insight into the molecular heterogeneity of cervical cancer and paves the way for developing molecularly targeted therapies. | Krystyna Serkies Jacek Jassem | 2018 | Chinese Journal of Cancer Research2018，30，2： | 26 |
| 2 | Developing a donation after cardiac death risk index for adult and pediatric liver transplantation显示文摘AIM To identify objective predictive factors for donor after cardiac death(DCD) graft loss and using those factors, develop a donor recipient stratification risk predictive model that could be used to calculate a DCD risk index(DCD-RI) to help in prospective decision making on organ use.METHODS The model included objective data from a single institute DCD database(2005-2013, n = 261). Univariate survival analysis was followed by adjusted Cox-regressional hazard model. Covariates selected via univariate regression were added to the model via forward selection, significance level P = 0.3. The warm ischemic threshold was clinically set at 30 min. Points were given to each predictor in proportion to their hazard ratio. Using this model, the DCD-RI was calculated. The cohort was stratified to predict graft loss risk and respective graft survival calculated.RESULTS DCD graft survival predictors were primary indication for transplant(P = 0.066), retransplantation(P = 0.176), MELD > 25(P = 0.05), cold ischemia > 10 h(P = 0.292) and donor hepatectomy time > 60 min(P = 0.028).According to the calculated DCD-RI score three risk classes could be defined of low(DCD-RI < 1), standard(DCD-RI 2-4) and high risk(DCD-RI > 5) with a 5 years graft survival of 86%, 78% and 34%, respectively.CONCLUSION The DCD-RI score independently predicted graft loss(P < 0.001) and the DCD-RI class predicted graft survival(P < 0.001). | Shirin Elizabeth Khorsandi Emmanouil Giorgakis Hector Vilca-Melendez John O'Grady Michael Heneghan Varuna Aluvihare Abid Suddle Kosh Agarwal Krishna Menon Andreas Prachalias Parthi Srinivasan Mohamed Rela Wayel Jassem Nigel Heaton | 2017 | World Journal of Transplantation2017，7，3： | 3 |
| 3 | Biliary Complications After Liver Transplantation Using Grafts from Donors After Cardiac Death: Results from a Matched Control Study in a Single Large Volume Center显示文摘 | Michelle L. DeOliveira Wayel Jassem Roberto Valente Shirin Elizabeth Khorsandi Gregorio Santori Andreas Prachalias Parthi Srinivasan Mohamed Rela Nigel Heaton | 2011 | Annals of Surgery2011，，5： | 2 |
| 4 | Prognostic relavance of proliferation cell nuclear antigen and p53 expression in non-small cell ltmg cancer显示文摘 | Dworakowska D Gozdz S Jassem E | 2002 | Lung Cancer2002，35，1： | 1 |
| 5 | The role of mitochondria in ischemia/reperfusion injury in organ transplantation显示文摘 | Jassem W Heaton ND | 2004 | Kidney Int2004，66，2： | 1 |
| 6 | Doxorubiein and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial 显示文摘 | Jassem J Pienkowski T Pluzanska A | 2009 | Onkologie2009，32，89： | 1 |
| 7 | Chlamydophila pneumoniae,Mycoplasma pneumoniae infections,and asthma control显示文摘 | Specjalski K Jassem E | 2011 | Allergy Asthma Proc2011，32，2： | 1 |
| 8 | Biliary complications after liver transplantation using grafts from donors after cardiac death : results from a matched control study in a single large volume center 显示文摘 | DeOliveira ML Jassem W Valente R | 2011 | Ann Surg2011，254，5： | 1 |
| 9 | Randomized, open label, phase Ⅲ trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non- small cell lung cancer (NSCLC)显示文摘 | Jassem J Langer CJ Karp DD | 2010 | J Clin Oncol2010，28，： | 1 |
| 10 | A Phase Ⅱ study of gemcitabine plus cisplatin in patients with advanced non-samall cell lung cancer:clinical outcomes and quality of life显示文摘 | Jassem J Krzakowski M Roszkowski K | 2002 | Lung Cancer2002，35，： | 1 |
| 11 | Liver transplantation after ex vivo normothermic machine preservation: a Phase 1 (first-in- man) clinical trial显示文摘 | Ravikumar R Jassem W Mergental H | 2016 | Am J Transplant2016，16，6： | 1 |
| 12 | First mature analysis of the intergroup Exemestane study显示文摘 | Coombes RC Paridaens R Jassem J | 2006 | J Clin Oncol2006，24，18： | 1 |
| 13 | Chemotherapy with mitomycine,ifosfamide,and cisplatin for recurrent or persistent cervical cancer显示文摘 | Serkies K Jassem J Dziadziuszko R | 2006 | Int J Gynecol Cancer2006，16，3： | 1 |
| 14 | Gemcitabine and anthracyclines in breast can cer显示文摘 | | 2003 | Semin Oncol2003，30，23： | 1 |
| 15 | Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer显示文摘 | Dworakowska D Jassem E Jassem J | 2009 | Lung Cancer2009，66，1： | 1 |
| 16 | Phase III trim comparing vinflunine with docetaxet in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy 显示文摘 | Krzakowski M Ramlau R Jassem J | 2010 | J Clin Oncol2010，28，13： | 1 |
| 17 | The role of mitochondria in ischemia/reperfusion injury显示文摘 | Jassem W Fuggle SV Rela M | 2002 | Transplantation2002，73，4： | 1 |
| 18 | Chlamydophila pneumoniae,Mycoplasma pneumoniae infections,and asthma control显示文摘 | Specjalski K Jassem E | 2011 | Allergy Asthma Proc2011，32，2： | 1 |
| 19 | Randomized phase II study(EORTC08062)ofamrubicin as single agent or in combination withcisplatin versus etoposide-cisplatin as first-line treatment in patients(pts)with extensive disease small cell lung Cancer(ED SCLC)显示文摘 | Brien M Jassem J Lorigan P | 2010 | J Clin Oncol2010，28，15： | 1 |
| 20 | Doxorubicin and paclitaxel versus fiuorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase Ⅲmulticenter trial 显示文摘 | Jassem J Pienkowski T Pluzanska A | 2001 | J Clin Oncol2001，19，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员